Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine: Results of a prospective multi-center study at certified breast centers
Objective - Biomarkers uPA and PAI-1 are guideline recommended by ASCO (USA) and AGO (Germany) in primary breast cancer to avoid unnecessary CTX in patients at medium risk for recurrence. For clinical quality assurance of uPA/PAI-1 testing, analysis of test-therapy concordance was performed. - Metho...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
October 2016
|
| In: |
The breast
Year: 2016, Jahrgang: 29, Pages: 208-212 |
| ISSN: | 1532-3080 |
| DOI: | 10.1016/j.breast.2016.06.014 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.breast.2016.06.014 Verlag: http://www.sciencedirect.com/science/article/pii/S0960977616300881 
|
| Verfasserangaben: | Volker R. Jacobs, Doris Augustin, Arthur Wischnik, Marion Kiechle, Cornelia Hoess, Oliver Steinkohl, Brigitte Rack, Thomas Kapitza, Peter Krase |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1684171040 | ||
| 003 | DE-627 | ||
| 005 | 20240403193237.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191204s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.breast.2016.06.014 |2 doi | |
| 035 | |a (DE-627)1684171040 | ||
| 035 | |a (DE-599)KXP1684171040 | ||
| 035 | |a (OCoLC)1341280451 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Jacobs, Volker Rudolf |d 1965- |e VerfasserIn |0 (DE-588)121542173 |0 (DE-627)70552292X |0 (DE-576)292763409 |4 aut | |
| 245 | 1 | 0 | |a Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine |b Results of a prospective multi-center study at certified breast centers |c Volker R. Jacobs, Doris Augustin, Arthur Wischnik, Marion Kiechle, Cornelia Hoess, Oliver Steinkohl, Brigitte Rack, Thomas Kapitza, Peter Krase |
| 264 | 1 | |c October 2016 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.12.2019 | ||
| 500 | |a Available online 23 June 2016 | ||
| 520 | |a Objective - Biomarkers uPA and PAI-1 are guideline recommended by ASCO (USA) and AGO (Germany) in primary breast cancer to avoid unnecessary CTX in patients at medium risk for recurrence. For clinical quality assurance of uPA/PAI-1 testing, analysis of test-therapy concordance was performed. - Methods - Prospective non-interventional multi-center study over 2 years among six Certified Breast Centers in Germany to investigate uPA/PAI-1 results in consecutive decision making for tumor board recommendation and actual therapy in uninfluenced clinical setting. Concordance and discordance rates of uPA/PAI-1 testing were calculated and individual reasons for decision making analyzed. - Results - Among n = 93 uPA/PAI-1 tests evaluated n = 42/93 (45.2%) were uPA + PAI-1 negative and n = 51/93 (54.8%) uPA and/or PAI-1 positive. In uPA + PAI-1 negative test results in n = 35/42 (83.3%) CTX was avoided as recommended. But in n = 7/42 (16.7%) CTX was performed despite, resulting in over treatment. In uPA and/or PAI-1 positive test results in n = 26/51 (51.0%) CTX was performed but in n = 25/51 (49.0%) not despite recommendation for CTX which is under treatment. The conformity of uPA/PAI-1 test result vs. tumor board decision was n = 73/93 (78.5%). The overall concordance of uPA/PAI-1 test result vs. consecutive therapy was n = 61/93 (65.6%). A variety of reasons for individual result-deviating decisions were identified. - Conclusions - Clinical quality assurance of uPA/PAI-1 biomarker testing showed inconsistency of test results with consecutive tumor board decision and/or final therapy performed in up to 1/3 of patients. To close this clinical quality gap in application of uPA/PAI-1 biomarkers, individual analysis of deviations is suggested with process optimization accordingly. | ||
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Cost | |
| 650 | 4 | |a Decision making | |
| 650 | 4 | |a Quality assurance | |
| 650 | 4 | |a Tumor board | |
| 700 | 1 | |a Wischnik, Arthur |d 1952- |e VerfasserIn |0 (DE-588)1067478655 |0 (DE-627)818787961 |0 (DE-576)426689615 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The breast |d Amsterdam [u.a.] : Elsevier, 1992 |g 29(2016), Seite 208-212 |h Online-Ressource |w (DE-627)320475042 |w (DE-600)2009043-2 |w (DE-576)103868151 |x 1532-3080 |7 nnas |a Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine Results of a prospective multi-center study at certified breast centers |
| 773 | 1 | 8 | |g volume:29 |g year:2016 |g pages:208-212 |g extent:5 |a Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine Results of a prospective multi-center study at certified breast centers |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.breast.2016.06.014 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0960977616300881 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20191204 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1067478655 |a Wischnik, Arthur |m 1067478655:Wischnik, Arthur |d 60000 |d 61300 |e 60000PW1067478655 |e 61300PW1067478655 |k 0/60000/ |k 1/60000/61300/ |p 3 | ||
| 999 | |a KXP-PPN1684171040 |e 3556353113 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 04.12.2019","Available online 23 June 2016"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"recId":"1684171040","person":[{"display":"Jacobs, Volker Rudolf","roleDisplay":"VerfasserIn","role":"aut","family":"Jacobs","given":"Volker Rudolf"},{"display":"Wischnik, Arthur","roleDisplay":"VerfasserIn","role":"aut","family":"Wischnik","given":"Arthur"}],"title":[{"subtitle":"Results of a prospective multi-center study at certified breast centers","title":"Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine","title_sort":"Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine"}],"physDesc":[{"extent":"5 S."}],"relHost":[{"id":{"issn":["1532-3080"],"eki":["320475042"],"zdb":["2009043-2"]},"origin":[{"publisherPlace":"Amsterdam [u.a.] ; Burlington, Mass.","dateIssuedKey":"1992","publisher":"Elsevier ; Harcourt","dateIssuedDisp":"1992-"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"The breast","title_sort":"breast"}],"language":["eng"],"recId":"320475042","type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine Results of a prospective multi-center study at certified breast centersThe breast","note":["Gesehen am 27.04.2020","Fortsetzung der Druck-Ausgabe"],"part":{"year":"2016","pages":"208-212","text":"29(2016), Seite 208-212","volume":"29","extent":"5"},"pubHistory":["1.1992 -"]}],"name":{"displayForm":["Volker R. Jacobs, Doris Augustin, Arthur Wischnik, Marion Kiechle, Cornelia Hoess, Oliver Steinkohl, Brigitte Rack, Thomas Kapitza, Peter Krase"]},"origin":[{"dateIssuedDisp":"October 2016","dateIssuedKey":"2016"}],"id":{"doi":["10.1016/j.breast.2016.06.014"],"eki":["1684171040"]}} | ||
| SRT | |a JACOBSVOLKCONCORDANC2016 | ||